Scheemaeker, Stephanie; Inglebert, Marine; Daminet, Sylvie; Dettwiler, Martina; Letko, Anna; Drögemüller, Cord; Kessler, Martin; Ducatelle, Richard; Rottenberg, Sven; Campos, Miguel (2023). Organoids of patient-derived medullary thyroid carcinoma: the first milestone towards a new in vitro model in dogs. Veterinary and comparative oncology, 21(1), pp. 111-122. Wiley 10.1111/vco.12872
|
Text
Vet_Comparative_Oncology_-_2022_-_Scheemaeker_-_Organoids_of_patient_derived_medullary_thyroid_carcinoma_the_first.pdf - Accepted Version Available under License Publisher holds Copyright. Download (5MB) | Preview |
Organoid cultures could constitute a valuable in vitro model to explore new treatments for canine (c) medullary thyroid carcinoma (MTC). The study's objectives were to establish and characterize 3D organoid cultures of cMTC using histology and immunohistochemistry (IHC) and to evaluate the effect of antitumor drugs on organoids' viability. Five cMTC tissue samples were used to develop organoid cultures of which one organoid line, named cMTC N°2, could be passaged for an extended period. This cMTC N°2 organoid line was further compared to the primary tumor regarding morphology and IHC expression of thyroid transcription factor-1 (TTF-1), thyroglobulin, calcitonin, synaptophysin, vimentin, Ki-67, cyclooxygenase-2 (COX-2), P-glycoprotein and vascular endothelial growth factor (VEGF). Quality control of the cMTC N°2 organoid line was achieved by a single nucleotide polymorphism (SNP) array of the organoids, primary tumor and healthy blood cells of the same dog. The effect of carboplatin, meloxicam and toceranib phosphate (TOC) on cMTC N°2 organoids' viability was evaluated. The cMTC N°2 organoid line was cultured for 94 days and showed similar histological features with the primary tumor. Immunolabeling for TTF-1, thyroglobulin, calcitonin and VEGF was similar between the primary tumor and cMTC N°2 organoids. Compared to the primary tumor, organoids showed higher immunolabeling for vimentin and Ki-67, and lower immunolabeling for synaptophysin, COX-2 and P-glycoprotein. The SNP genotype was similar for each chromosome between healthy blood cells, primary tumor and cMTC N°2 organoids. Carboplatin, meloxicam and TOC had no effect on cMTC N°2 organoid cell viability within achievable in vivo concentration range. In conclusion, the cMTC N°2 organoid line is a promising first milestone towards an established in vitro organoid model to explore pathophysiology and new treatment modalities in cMTC. This article is protected by copyright. All rights reserved.
Actions (login required)
 |
Edit item |